# Gerd R Burmester

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/gerd-r-burmester/

## Facts

| Field | Value |
| --- | --- |
| Citations | 65,038 |
| Field | Rheumatoid Arthritis Research and Therapies |
| h-index | 116 |
| i10-index | 428 |
| Last Known Institution | Charité - Universitätsmedizin Berlin |
| OpenAlex ID | https://openalex.org/A5076851275 |
| ORCID iD | https://orcid.org/0000-0001-7518-1131 |
| Works | 961 |

## Researcher papers

- [2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative](https://scholariq.org/papers/2010-rheumatoid-arthritis-classification-criteria-an-american-college-of-2/)
- [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic-2/)
- [Rheumatoid arthritis](https://scholariq.org/papers/rheumatoid-arthritis-2/)
- [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic-3/)
- [\nEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.](https://scholariq.org/papers/neular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic/)
- [Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force](https://scholariq.org/papers/treating-rheumatoid-arthritis-to-target-2014-update-of-the-recommendations-of-an/)
- [European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update](https://scholariq.org/papers/european-league-against-rheumatism-eular-recommendations-for-the-management-of/)
- [Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial](https://scholariq.org/papers/tofacitinib-cp-690-550-in-combination-with-methotrexate-in-patients-with-active/)
- [Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)](https://scholariq.org/papers/sustained-benefits-of-infliximab-therapy-for-dermatologic-and-articular/)
- [2016 update of the EULAR recommendations for the management of early arthritis](https://scholariq.org/papers/2016-update-of-the-eular-recommendations-for-the-management-of-early-arthritis/)

## Researcher topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)

## Researcher university

- [Charité - Universitätsmedizin Berlin](https://scholariq.org/institutions/charite-universitatsmedizin-berlin/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.